Following the success of obesity treatments, global pharmaceutical and biotech industries are increasingly focusing on the ...

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

Add Yahoo as a preferred source to see more of our stories on Google. A Halloween conspiracy theory going viral on Twitter has social media users coming to a startling realization about Bobby ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease ...

Welcome to Overthinking It, a new Esquire series in which editors and writers dig into a very, very specific moment in pop culture—putting our dogged journalistic and critical skills to use in the ...

In this episode, 'Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH,' the hepatologist Nadege Gunn, MD explores the following questions: 1. How would you characterize the ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a “silent disease” that often has no early symptoms, yet can progress to cirrhosis or liver failure. Possible MASH symptoms include ...

NEW YORK, NEW YORK - JUNE 21: Dan Marino speaks onstage at Fanatics Fest NYC 2025 at Javits Center on June 21, 2025 in New York City. (Photo by Slaven Vlasic/Getty Images) To say that Dan Marino has ...